依达拉奉联合丹参川芎嗪治疗急性脑梗死患者效果观察

Clinical effect of edaravone combined with salvia ligustrazine on patients with acute cerebral infarction

目的:探讨使用依达拉奉联合丹参川芎嗪治疗急性脑梗死的效果。方法:选取本院收治的100例急性脑梗死患者为研究对象,随机分成观察组(n=50)与对照组(n=50),均先予常规治疗,在此基础上对照组使用依达拉奉注射液治疗,观察组在对照组的用药基础上,加用丹参川芎嗪注射液治疗,比较两组治疗效果。结果:治疗前,在NIHSS评分与ADL评分上两组差异无统计学意义(P>0.05),而治疗后两组NIHSS评分均降低,ADL评分均提高,但治疗后观察组NIHSS评分明显较对照组低,ADL评分明显较对照组高,组间对比差异具有统计学意义(P<0.05);观察组治疗总有效率为96.00%,对照组82.00%,差异具有统计学意义(P<0.05)。结论:临床治疗中采取依达拉奉联合丹参川芎嗪的联合用药方式治疗急性脑梗死,改善患者神经功能缺损情况,提高患者生活能力,适合临床应用。

Objective:To investigate the effect of edaravone combined with salvia ligustrazine on acute cerebral infarction.Methods:100 cases of acute cerebral infarction patients treated in our hospital were selected as the subjects,who were randomized into the observation group(n=50)and control group(n=50).Both groups received conventional therapy at first,then edaravone injection was used for the control group,while salvia ligustrazine injection was added to the observation group on the above-mentioned basis.The efficacy was compared between both groups.Results:Before treatment,there was no significant difference between NIHSS score and ADL score for the two groups(P>0.05);while after treatment,the NIHSS score of the two groups decreased and the ADL score increased,but after treatment,the NIHSS score of the observation group was significantly lower than that of the control group,and the ADL score was significantly higher than that of the control group,which were of statistical differences between both groups(P<0.05);the total effective rate of the observation group and control group was 96.00%and 82.00%respectively,which was of statistical significance(P<0.05).Conclusion:Edaravone combined with salvia ligustrazine can achieve satisfactory curative effect in the clinical treatment of acute cerebral infarction,improve the neurological function of patients and their living abilities,and it is worthy of clinical promotion.